Riluzole and its prodrugs for the treatment of Alzheimer's disease.
Alzheimer’s disease
cognitive decline
glutamatergic excitotoxicity
prodrugs
riluzole
Journal
Pharmaceutical patent analyst
ISSN: 2046-8962
Titre abrégé: Pharm Pat Anal
Pays: England
ID NLM: 101582615
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
pmc-release:
01
03
2024
medline:
8
6
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
ppublish
Résumé
Current medications for Alzheimer's disease help manage symptoms and behavioral problems. Nevertheless, they do not slow the progression of cognitive decline or dementia. A potential approach for treating Alzheimer's disease is to target neurons that are sensitive to disease pathobiology such as glutamatergic neurons. Several patents disclosed methods for treating Alzheimer's disease by administering riluzole or its prodrugs. Clinical trials revealed that 6 months treatment using riluzole or troriluzole is associated with a slower decline in the tomographic measures of the positron emissions of cerebral glucose metabolism in Alzheimer's patients. The proposed strategy claims to prevent and/or slow the cognitive decline of Alzheimer's patients and to enhance global functioning. These claims may also pave the way for other glutamate modulators to be used for Alzheimer's disease.
Identifiants
pubmed: 37140357
doi: 10.4155/ppa-2023-0001
pmc: PMC10318568
doi:
Substances chimiques
Riluzole
7LJ087RS6F
Prodrugs
0
Neuroprotective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-85Subventions
Organisme : NIGMS NIH HHS
ID : SC3 GM131986
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC3GM131986
Pays : United States
Références
Prog Brain Res. 2002;136:467-86
pubmed: 12143403
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Nat Rev Neurosci. 2016 Apr;17(4):201-7
pubmed: 26911435
J Neuroinflammation. 2014 Mar 22;11:54
pubmed: 24655894
J Neurosci Res. 2004 Jul 1;77(1):1-8
pubmed: 15197750
Curr Opin Neurobiol. 2008 Jun;18(3):321-31
pubmed: 18804167
Neuroscientist. 2023 Aug;29(4):461-471
pubmed: 35073787
Nat Neurosci. 2014 Jan;17(1):131-43
pubmed: 24316888
J Neurochem. 2021 Feb;156(4):513-523
pubmed: 33107040
EMBO Mol Med. 2018 Nov;10(11):
pubmed: 30224383
Transl Psychiatry. 2018 Aug 14;8(1):153
pubmed: 30108205
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18733-8
pubmed: 25512503
J Comp Neurol. 1990 Nov 1;301(1):55-64
pubmed: 1706358
Amyotroph Lateral Scler. 2007 Oct;8(5):305-9
pubmed: 17852022
N Engl J Med. 2014 Jan 23;370(4):322-33
pubmed: 24450891
Br J Pharmacol. 2012 Sep;167(2):324-52
pubmed: 22646481
Nat Rev Neurosci. 2006 Jul;7(7):575-83
pubmed: 16791146
J Alzheimers Dis. 2018;61(1):435-457
pubmed: 29154277
Nat Rev Neurosci. 2010 Oct;11(10):682-96
pubmed: 20842175
Brain. 2021 Dec 31;144(12):3742-3755
pubmed: 34145880
Clin Pharmacol Ther. 1997 Nov;62(5):518-26
pubmed: 9390108
J Neuroinflammation. 2018 Mar 28;15(1):98
pubmed: 29592816
Aging (Albany NY). 2020 Feb 8;12(3):3095-3113
pubmed: 32035419
J Comp Neurol. 1990 Nov 1;301(1):44-54
pubmed: 2127598
Cell. 2019 Oct 3;179(2):312-339
pubmed: 31564456
Mol Psychiatry. 2017 Feb;22(2):296-305
pubmed: 27021815